Login to Your Account



FDA wants broader study populations, with more elderly

By Randy Osborne
Staff Writer

Monday, February 3, 2014
The FDA’s Center for Drug Evaluation and Research (CDER) is ramping up efforts to make certain that clinical trials include wide enough breadths of patient populations, and don’t unnecessarily keep out subjects with multiple chronic conditions (MCCs) who could turn up important data that would otherwise be missed.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription